Three F.D.A. Advisers Resign Over Agency’s Approval of Alzheimer’s Drug

by

The drug, Aduhelm, a monthly infusion priced at $56,000 per year, was approved this week despite weak evidence that it helps patients.

View original article
Contributor: Pam Belluck and Rebecca Robbins